These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37972434)

  • 21. Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation.
    Dou X; Sun Q; Liu Y; Lu Y; Zhang C; Xu G; Xu Y; Huo T; Zhao X; Su L; Xing Y; Lai L; Jiao N
    Bioorg Med Chem Lett; 2024 Jan; 97():129547. PubMed ID: 37944867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
    Fink EA; Bardine C; Gahbauer S; Singh I; Detomasi TC; White K; Gu S; Wan X; Chen J; Ary B; Glenn I; O'Connell J; O'Donnell H; Fajtová P; Lyu J; Vigneron S; Young NJ; Kondratov IS; Alisoltani A; Simons LM; Lorenzo-Redondo R; Ozer EA; Hultquist JF; O'Donoghue AJ; Moroz YS; Taunton J; Renslo AR; Irwin JJ; García-Sastre A; Shoichet BK; Craik CS
    Protein Sci; 2023 Aug; 32(8):e4712. PubMed ID: 37354015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
    Gao S; Sylvester K; Song L; Claff T; Jing L; Woodson M; Weiße RH; Cheng Y; Schäkel L; Petry M; Gütschow M; Schiedel AC; Sträter N; Kang D; Xu S; Toth K; Tavis J; Tollefson AE; Müller CE; Liu X; Zhan P
    J Med Chem; 2022 Oct; 65(19):13343-13364. PubMed ID: 36107752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
    Dou X; Sun Q; Xu G; Liu Y; Zhang C; Wang B; Lu Y; Guo Z; Su L; Huo T; Zhao X; Wang C; Yu Z; Song S; Zhang L; Liu Z; Lai L; Jiao N
    Eur J Med Chem; 2022 Aug; 238():114508. PubMed ID: 35688005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors.
    Guo N; Huang C; Qiao J; Li Y; Wang Y; Xia A; Zhang G; Fang Z; You J; Li L
    Bioorg Med Chem Lett; 2023 Apr; 86():129238. PubMed ID: 36924946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
    Parise A; Romeo I; Russo N; Marino T
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.
    Ciaglia T; Vestuto V; Di Sarno V; Musella S; Smaldone G; Di Matteo F; Napolitano V; Miranda MR; Pepe G; Basilicata MG; Novi S; Capolupo I; Bifulco G; Campiglia P; Gomez-Monterrey I; Snoeck R; Andrei G; Manfra M; Ostacolo C; Lauro G; Bertamino A
    Eur J Med Chem; 2024 Feb; 266():116128. PubMed ID: 38232463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
    Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
    Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
    [No Abstract]   [Full Text] [Related]  

  • 30. Green and efficient one-pot three-component synthesis of novel drug-like furo[2,3-d]pyrimidines as potential active site inhibitors and putative allosteric hotspots modulators of both SARS-CoV-2 M
    Mousavi H; Zeynizadeh B; Rimaz M
    Bioorg Chem; 2023 Jun; 135():106390. PubMed ID: 37037129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining virtual screening with cis-/trans-cleavage enzymatic assays effectively reveals broad-spectrum inhibitors that target the main proteases of SARS-CoV-2 and MERS-CoV.
    Chang YJ; Le UNP; Liu JJ; Li SR; Chao ST; Lai HC; Lin YF; Hsu KC; Lu CH; Lin CW
    Antiviral Res; 2023 Aug; 216():105653. PubMed ID: 37321487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
    Pang X; Xu W; Liu Y; Li H; Chen L
    Eur J Med Chem; 2023 Sep; 257():115491. PubMed ID: 37244162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
    Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
    Alugubelli YR; Geng ZZ; Yang KS; Shaabani N; Khatua K; Ma XR; Vatansever EC; Cho CC; Ma Y; Xiao J; Blankenship LR; Yu G; Sankaran B; Li P; Allen R; Ji H; Xu S; Liu WR
    Eur J Med Chem; 2022 Oct; 240():114596. PubMed ID: 35839690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability.
    Gao S; Song L; Sylvester K; Mercorelli B; Loregian A; Toth K; Weiße RH; Useini A; Sträter N; Yang M; Ye B; Tollefson AE; Müller CE; Liu X; Zhan P
    J Med Chem; 2023 Dec; 66(23):16426-16440. PubMed ID: 37992202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity.
    Li J; Zhang Y; Pang H; Li SJ
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Feb; 267(Pt 2):120595. PubMed ID: 34815178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection.
    Ge R; Shen Z; Yin J; Chen W; Zhang Q; An Y; Tang D; Satz AL; Su W; Kuai L
    SLAS Discov; 2022 Mar; 27(2):79-85. PubMed ID: 35063690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system.
    Komatsu H; Tanaka T; Ye Z; Ikeda K; Matsuzaki T; Yasugi M; Hosoda M
    J Biomol Struct Dyn; 2023 Mar; 41(5):1767-1775. PubMed ID: 34984963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.